1 CONFIDENTIAL – DO NOT DISTRIBUTE ARIES mCRC: Effectiveness and Safety of 1st- and 2nd-line...
-
Upload
polly-farmer -
Category
Documents
-
view
216 -
download
0
description
Transcript of 1 CONFIDENTIAL – DO NOT DISTRIBUTE ARIES mCRC: Effectiveness and Safety of 1st- and 2nd-line...
![Page 1: 1 CONFIDENTIAL – DO NOT DISTRIBUTE ARIES mCRC: Effectiveness and Safety of 1st- and 2nd-line Bevacizumab Treatment in Elderly Patients Mark Kozloff, MD.](https://reader036.fdocuments.net/reader036/viewer/2022062600/5a4d1b3e7f8b9ab05999fafe/html5/thumbnails/1.jpg)
1CONFIDENTIAL – DO NOT DISTRIBUTE
ARIES mCRC: Effectiveness and Safety of 1st- and 2nd-line Bevacizumab Treatment in
Elderly PatientsMark Kozloff, MD
![Page 2: 1 CONFIDENTIAL – DO NOT DISTRIBUTE ARIES mCRC: Effectiveness and Safety of 1st- and 2nd-line Bevacizumab Treatment in Elderly Patients Mark Kozloff, MD.](https://reader036.fdocuments.net/reader036/viewer/2022062600/5a4d1b3e7f8b9ab05999fafe/html5/thumbnails/2.jpg)
2CONFIDENTIAL–DO NOT DISTRIBUTE
BackgroundBackground
• A pooled analysis of 4 randomized trials showed that BV treatment was associated with statistically significant increases in PFS (HR 0.58) and OS (HR 0.85) in patients aged ≥65 y1
• In the BRiTE OCS of BV with 1st-line CT, median PFS was similar across age subgroups, while median OS declined with increasing age2
• With the exception of a higher incidence of ATEs in elderly patients, there do not appear to be substantial age-related increases in grade 3–5 AEs with BV treatment in the 1st-line setting1,2
• No studies to date have evaluated outcomes in elderly patients receiving BV with 2nd-line treatment
1. Cassidy J, et al. J Cancer Res Clin Oncol. 2010;136:737–743.2. Kozloff MF, et al. Oncology. 2010;78:329–339.
![Page 3: 1 CONFIDENTIAL – DO NOT DISTRIBUTE ARIES mCRC: Effectiveness and Safety of 1st- and 2nd-line Bevacizumab Treatment in Elderly Patients Mark Kozloff, MD.](https://reader036.fdocuments.net/reader036/viewer/2022062600/5a4d1b3e7f8b9ab05999fafe/html5/thumbnails/3.jpg)
3CONFIDENTIAL–DO NOT DISTRIBUTE
Objective and Patient PopulationObjective and Patient Population
• Objective– To evaluate baseline characteristics, effectiveness, and safety
associated with different age subgroups among patients receiving BV + CT in the 1st- or 2nd-line treatment of mCRC, with a special emphasis on the elderly
• Patient population– This analysis evaluated outcomes in 3 age-based subgroups of
patients receiving either 1st- or 2nd-line therapy: <70 y, 70–79 y, and ≥80 y
![Page 4: 1 CONFIDENTIAL – DO NOT DISTRIBUTE ARIES mCRC: Effectiveness and Safety of 1st- and 2nd-line Bevacizumab Treatment in Elderly Patients Mark Kozloff, MD.](https://reader036.fdocuments.net/reader036/viewer/2022062600/5a4d1b3e7f8b9ab05999fafe/html5/thumbnails/4.jpg)
4CONFIDENTIAL–DO NOT DISTRIBUTE
Enrollment, Follow-up, and Enrollment, Follow-up, and Baseline CharacteristicsBaseline Characteristics
• Median follow-up of 20.7 and 16.9 months in 1st- and 2nd-line cohorts, respectively
• Baseline characteristics – In general, a higher percentage of patients in the 70–79 y and ≥80 y subgroups
had an ECOG PS ≥1 (except in the ≥80 y 2nd-line subgroup), the colon as the primary tumor site, a history of cardiovascular disease, baseline hypertension requiring medication, and baseline hypercholesterolemia requiring medication compared with patients in the ≤70 y subgroup within the 1st- and 2nd-line cohorts
<70 y (n=1126)
≥80 y (n=113)
1st-line mCRC patients
(N=1550)
70–79 y (n=311)
<70 y (n=336)
≥80 y (n=40)
2nd-line mCRC patients (N=482)
70–79 y (n=106)
![Page 5: 1 CONFIDENTIAL – DO NOT DISTRIBUTE ARIES mCRC: Effectiveness and Safety of 1st- and 2nd-line Bevacizumab Treatment in Elderly Patients Mark Kozloff, MD.](https://reader036.fdocuments.net/reader036/viewer/2022062600/5a4d1b3e7f8b9ab05999fafe/html5/thumbnails/5.jpg)
5CONFIDENTIAL–DO NOT DISTRIBUTE
Baseline Chemotherapy by Age: Baseline Chemotherapy by Age: 1st-line Cohort1st-line Cohort
Pat
ient
s, %
(n=1126) (n=311) (n=113)
![Page 6: 1 CONFIDENTIAL – DO NOT DISTRIBUTE ARIES mCRC: Effectiveness and Safety of 1st- and 2nd-line Bevacizumab Treatment in Elderly Patients Mark Kozloff, MD.](https://reader036.fdocuments.net/reader036/viewer/2022062600/5a4d1b3e7f8b9ab05999fafe/html5/thumbnails/6.jpg)
6CONFIDENTIAL–DO NOT DISTRIBUTE
2nd-line Treatment by Age:2nd-line Treatment by Age:1st-line Cohort1st-line Cohort
• A higher percentage of patients <70 y received 2nd-line treatment (with or without BV) and had exposure to 3 active chemotherapy agents compared with the older age subgroups
Treatment
1st-line patients<70 y
(n=1126)70–79 y(n=311)
≥80 y(n=113)
Patients receiving 2nd-line therapy, no. (%)
734 (65) 179 (58) 50 (44)
Patients receiving BV in 2nd-line therapy, no. (%)
334 (30) 76 (24) 17 (15)
Patients with exposure to 3 active chemotherapies, no. (%)
617 (55) 130 (42) 31 (27)
![Page 7: 1 CONFIDENTIAL – DO NOT DISTRIBUTE ARIES mCRC: Effectiveness and Safety of 1st- and 2nd-line Bevacizumab Treatment in Elderly Patients Mark Kozloff, MD.](https://reader036.fdocuments.net/reader036/viewer/2022062600/5a4d1b3e7f8b9ab05999fafe/html5/thumbnails/7.jpg)
7CONFIDENTIAL–DO NOT DISTRIBUTE
Effectiveness Outcomes by Age: Effectiveness Outcomes by Age: 1st-line Cohort1st-line Cohort
• According to Kaplan-Meier analysis, 1st-line patients in the 70–79 y and ≥80 y subgroups had a similar PFS but significantly lower OS compared with 1st-line patients <70 y
Outcome
1st-line patients<70 y
(n=1126)70–79 y(n=311)
≥80 y(n=113)
Patients with a PFS event, no. (%) 1000 (88.8) 284 (91.3) 105 (92.9)
Median PFS, mos 10.3 10.1 9.4
Deaths, no. (%) 735 (65.3) 227 (73.0) 93 (82.3)
Median OS, mos 25.1 20.8 18.5
![Page 8: 1 CONFIDENTIAL – DO NOT DISTRIBUTE ARIES mCRC: Effectiveness and Safety of 1st- and 2nd-line Bevacizumab Treatment in Elderly Patients Mark Kozloff, MD.](https://reader036.fdocuments.net/reader036/viewer/2022062600/5a4d1b3e7f8b9ab05999fafe/html5/thumbnails/8.jpg)
8CONFIDENTIAL–DO NOT DISTRIBUTE
Kaplan-Meier Estimate of PFS Kaplan-Meier Estimate of PFS in the 1st-line Cohortin the 1st-line Cohort
![Page 9: 1 CONFIDENTIAL – DO NOT DISTRIBUTE ARIES mCRC: Effectiveness and Safety of 1st- and 2nd-line Bevacizumab Treatment in Elderly Patients Mark Kozloff, MD.](https://reader036.fdocuments.net/reader036/viewer/2022062600/5a4d1b3e7f8b9ab05999fafe/html5/thumbnails/9.jpg)
9CONFIDENTIAL–DO NOT DISTRIBUTE
Kaplan-Meier Estimate of OS Kaplan-Meier Estimate of OS in the 1st-line Cohortin the 1st-line Cohort
![Page 10: 1 CONFIDENTIAL – DO NOT DISTRIBUTE ARIES mCRC: Effectiveness and Safety of 1st- and 2nd-line Bevacizumab Treatment in Elderly Patients Mark Kozloff, MD.](https://reader036.fdocuments.net/reader036/viewer/2022062600/5a4d1b3e7f8b9ab05999fafe/html5/thumbnails/10.jpg)
10CONFIDENTIAL–DO NOT DISTRIBUTE
Multivariate Analysis in Multivariate Analysis in 1st-line Cohort1st-line Cohort
Outcome Hazard ratio (95% CI)PFS in 1st-line patients <70 y 70–79 y ≥80 y
1.0 (reference)1.07 (0.93, 1.22)1.18 (0.95, 1.46)
OS in 1st-line patients <70 y 70–79 y ≥80 y
1.0 (reference)
1.15 (0.98, 1.34)1.55 (1.23, 1.96)
• According to multivariate analyses, all age subgroups had a similar PFS profile in the 1st-line cohort
• Patients ≥80 y had an elevated risk of all-cause mortality compared to those <70 y
• Patients 70–79 y had a similar risk of all-cause mortality as those <70 y
Adjusted for the following baseline covariates: sex, race, ECOG PS, diabetes, hypertension, hypercholesterolemia, cardiovascular disease history, albumin level, alkaline phosphatase level, site of primary tumor, surgical resection,and adjuvant therapy.
![Page 11: 1 CONFIDENTIAL – DO NOT DISTRIBUTE ARIES mCRC: Effectiveness and Safety of 1st- and 2nd-line Bevacizumab Treatment in Elderly Patients Mark Kozloff, MD.](https://reader036.fdocuments.net/reader036/viewer/2022062600/5a4d1b3e7f8b9ab05999fafe/html5/thumbnails/11.jpg)
11CONFIDENTIAL–DO NOT DISTRIBUTE
Timing of Targeted Adverse Events Timing of Targeted Adverse Events by Age: 1st-line Cohortby Age: 1st-line Cohort
Outcome<70 y
(n=1126)70–79 y(n=311)
≥80 y(n=113)
Targeted AEs by interval, n (%) Any time Months 0–<3 Months 3–<6 Months 6–<9 Months 9–53
253 (22.5)107 (9.5)65 (6.6)29 (3.6)52 (8.9)
75 (24.1)28 (9.0)20 (7.6)9 (4.4)
18 (12.5)
21 (18.6)9 (8.0)5 (5.6)4 (6.0)3 (8.1)
Serious AEs by interval, n (%) Any time Months 0–<3 Months 3–<6 Months 6–<9 Months 9–53
102 (9.1)41 (3.6)24 (2.3)9 (1.0)28 (4.2)
42 (13.5)14 (4.5)10 (3.6)6 (2.7)12 (7.5)
11 (9.7)7 (6.2)2 (2.2)1 (1.4)1 (2.4)
GI perforations at any time, n (%) 11 (1.0) 3 (1.0) 0 (0)
Grade 3–5 bleeding at any time, n (%) 27 (2.4) 14 (4.5) 6 (5.3)
ATEs at any time, n (%) 19 (1.7) 13 (4.2) 3 (2.7)
VTEs at any time, n (%) 84 (7.5) 21 (6.8) 6 (5.3)
Hypertension requiring management, n (%) 105 (9.3) 21 (6.8) 4 (3.5)
![Page 12: 1 CONFIDENTIAL – DO NOT DISTRIBUTE ARIES mCRC: Effectiveness and Safety of 1st- and 2nd-line Bevacizumab Treatment in Elderly Patients Mark Kozloff, MD.](https://reader036.fdocuments.net/reader036/viewer/2022062600/5a4d1b3e7f8b9ab05999fafe/html5/thumbnails/12.jpg)
12CONFIDENTIAL–DO NOT DISTRIBUTE
Baseline Chemotherapy by Age: Baseline Chemotherapy by Age: 2nd-line Cohort2nd-line Cohort
Pat
ient
s, %
(n=336) (n=106) (n=40)
• 76%, 64%, and 55% of patients in <70y, 70–79 y, and ≥80 y subgroups had exposure to 3 active chemotherapy agents
![Page 13: 1 CONFIDENTIAL – DO NOT DISTRIBUTE ARIES mCRC: Effectiveness and Safety of 1st- and 2nd-line Bevacizumab Treatment in Elderly Patients Mark Kozloff, MD.](https://reader036.fdocuments.net/reader036/viewer/2022062600/5a4d1b3e7f8b9ab05999fafe/html5/thumbnails/13.jpg)
13CONFIDENTIAL–DO NOT DISTRIBUTE
Effectiveness Outcomes by Age: Effectiveness Outcomes by Age: 2nd-line Cohort2nd-line Cohort
• In the 2nd-line cohort, no significant differences in PFS or OS by age were observed according to Kaplan-Meier analysis
Outcome
2nd-line patients<70 y
(n=336)70–79 y(n=106)
≥80 y(n=40)
Patients with a PFS event, no. (%) 311 (92.6) 103 (97.2) 35 (87.5)
Median PFS, mos 7.9 8.0 6.7
Deaths, no. (%) 261 (77.7) 87 (82.1) 34 (85.0)
Median OS, mos 18.6 17.5 14.9
![Page 14: 1 CONFIDENTIAL – DO NOT DISTRIBUTE ARIES mCRC: Effectiveness and Safety of 1st- and 2nd-line Bevacizumab Treatment in Elderly Patients Mark Kozloff, MD.](https://reader036.fdocuments.net/reader036/viewer/2022062600/5a4d1b3e7f8b9ab05999fafe/html5/thumbnails/14.jpg)
14CONFIDENTIAL–DO NOT DISTRIBUTE
Kaplan-Meier Estimate of OS Kaplan-Meier Estimate of OS in the 2nd-line Cohortin the 2nd-line Cohort
![Page 15: 1 CONFIDENTIAL – DO NOT DISTRIBUTE ARIES mCRC: Effectiveness and Safety of 1st- and 2nd-line Bevacizumab Treatment in Elderly Patients Mark Kozloff, MD.](https://reader036.fdocuments.net/reader036/viewer/2022062600/5a4d1b3e7f8b9ab05999fafe/html5/thumbnails/15.jpg)
15CONFIDENTIAL–DO NOT DISTRIBUTE
Multivariate Analysis Multivariate Analysis in 2nd-line Cohortin 2nd-line Cohort
Outcome Hazard ratio (95% CI)PFS in 2nd-line patients <70 y 70–79 y ≥80 y
1.0 (reference)0.96 (0.76, 1.22)0.95 (0.66, 1.36)
OS in 2nd-line patients <70 y 70–79 y ≥80 y
1.0 (reference)1.07 (0.82, 1.39)1.54 (1.06, 2.24)
• As in the 1st-line cohort, all age subgroups had a similar PFS profile in the 2nd-line cohort according to multivariate analyses
• Patients ≥80 y, but not patients 70–79 y, had an elevated risk of all-cause mortality (ie, OS) compared to those <70 y
Adjusted for the following baseline covariates: sex, race, ECOG PS, diabetes, hypertension, hypercholesterolemia, cardiovascular disease history, albumin level, alkaline phosphatase level, site of primary tumor, surgical resection,and adjuvant therapy.
![Page 16: 1 CONFIDENTIAL – DO NOT DISTRIBUTE ARIES mCRC: Effectiveness and Safety of 1st- and 2nd-line Bevacizumab Treatment in Elderly Patients Mark Kozloff, MD.](https://reader036.fdocuments.net/reader036/viewer/2022062600/5a4d1b3e7f8b9ab05999fafe/html5/thumbnails/16.jpg)
16CONFIDENTIAL–DO NOT DISTRIBUTE
Timing of Targeted Adverse Events Timing of Targeted Adverse Events by Age: 2nd-line Cohortby Age: 2nd-line Cohort
Outcome<70 y
(n=336)70–79 y(n=106)
≥80 y(n=40)
Targeted AEs by interval, n (%) Any time Months 0–<3 Months 3–<6 Months 6–<9 Months 9–50
50 (14.9)17 (5.1)7 (2.3)7 (2.9)
19 (11.8)
17 (16.0) 7 (6.6)2 (2.1)3 (3.9)5 (10.2)
11 (27.5)4 (10.0)2 (6.3)3 (15.0)2 (15.4)
Serious AEs by interval, n (%) Any time Months 0–<3 Months 3–<6 Months 6–<9 Months 9–50
17 (5.1)7 (2.1)2 (0.6)1 (0.4)7 (4.1)
8 (7.5)4 (3.8)2 (2.1)0 (0)
2 (3.8)
7 (17.5)1 (2.5)1 (2.9)3 (13.6)2 (14.3)
GI perforations at any time, n (%) 1 (0.3) 2 (1.9) 1 (2.5)
Grade 3–5 bleeding at any time, n (%) 4 (1.2) 2 (1.9) 2 (5.0)
ATEs at any time, n (%) 4 (1.2) 1 (0.9) 3 (7.5)
VTEs at any time, n (%) 22 (6.5) 5 (4.7) 1 (2.5)
Hypertension requiring management, n (%) 15 (4.5) 4 (3.8) 2 (5.0)
![Page 17: 1 CONFIDENTIAL – DO NOT DISTRIBUTE ARIES mCRC: Effectiveness and Safety of 1st- and 2nd-line Bevacizumab Treatment in Elderly Patients Mark Kozloff, MD.](https://reader036.fdocuments.net/reader036/viewer/2022062600/5a4d1b3e7f8b9ab05999fafe/html5/thumbnails/17.jpg)
17CONFIDENTIAL–DO NOT DISTRIBUTE
Summary and ConclusionsSummary and Conclusions
• ARIES is the first study to describe the effects of 2nd-line BV treatment for mCRC in a large population of elderly patients
• In ARIES, PFS was similar across all age subgroups in both treatment lines; OS was shorter in patients ≥80 y compared with the youngest age subgroup, as is seen in the general population– These results are consistent with observations from the BRiTE OCS
• The incidence of targeted AEs and SAEs appeared to decrease over time in the first 9 months from the start of BV treatment, and there were no remarkable differences in the incidence patterns according to age
• In general, patients in the 70–79 y and ≥80 y age subgroups had a low overall incidence of targeted AEs and SAEs that was similar to that reported in patients <70 y
• This preliminary analysis suggests that BV treatment in elderly patients with mCRC may not be associated with poorer clinical or safety outcomes than in younger patients